Active Needle Selected for Global Business Innovation Programme in Singapore

We are delighted to announce that Active Needle Technology Ltd has been selected to join the Global Business Innovation Programme (GBIP) – Health and Medical Technologies, organised by the Innovate UK .

The programme connects leading UK innovators with partners and investors in Singapore’s world-class medical technology ecosystem. Over the next few months, Active Needle will take part in workshops, a market visit to Singapore, and follow-up support to build strategic collaborations and expand its international presence.

Participation in the GBIP represents a major opportunity for Active Needle to advance its HyPerfuse Needle™ technology — a patented ultrasonic needle system designed to deliver drugs with greater precision, safety and efficacy. The company aims to explore partnerships in oncology, diagnostics, and therapeutic delivery, aligning with Singapore’s Research, Innovation and Enterprise 2025 Plan, which emphasises precision medicine and minimally invasive healthcare innovations.

“Singapore represents a world-class hub for oncology innovation and a gateway to the wider Asia-Pacific MedTech market,” said Dr Muhammad Sadiq, Co-Founder and CTO of Active Needle Technology, who will represent the company on the programme. “Through GBIP, we aim to forge research and commercial partnerships that accelerate clinical adoption and help scale our ultrasonic delivery platform globally.”

The GBIP provides tailored support from Innovate UK specialists, helping companies like Active Needle refine market entry strategies, develop collaborations, and position themselves for international growth. For Active Needle, this marks another step forward in its mission to transform precision drug delivery and improve patient outcomes worldwide.